

# A multiplex bead platform for protein profiling of exosomes by flow cytometry

Stefan Wild<sup>1</sup>, Colin deBakker<sup>2</sup>, Nina Koliha<sup>1</sup>, Yvonne Wiencek<sup>1</sup>, Ute Heider<sup>1</sup>, and Andreas Bosio<sup>1</sup> <sup>1</sup>Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, <sup>2</sup>Miltenyi Biotec Inc., San Diego, CA, USA

# Background

Exosomes or extracellular vesicles (EVs) are loaded with specific sets of proteins, lipids, and nucleic acids. The EV composition depends on the originating cell and different EVs can be distinguished by

Methods

#### Multiplex bead-based assay

Color-coded polystyrene multiplex beads were incubated with isolated EVs in 300 μL PAP (PBS, 0.1% Pluronic<sup>®</sup> F127, 0.09% azide), cell culture supernatant, or ascites at 4 °C overnight. Beads were washed in PAP and centrifuged at 3,000×g for 5 min. The beads surface marker profiling. We established a multiplex bead-based assay consisting of capture and detection antibodies to analyze the composition of exosomal surface proteins by flow cytometry.

were resuspended in 100 µL PAP and bound EVs were stained with 0.5 µg detection antibody. Stained EVs on the multiplex beads can also be fixed by adding 100 µL Inside Fix (Miltenyi Biotec) for 20 minutes at room temperature.



### Results

#### Cancer cell EVs from melanoma or colon cancer display different surface markers

tumor markers. MSCP-positive EVs were captured from all melanoma samples. In contrast, melanoma EVs hardly showed any

EVs isolated from cancer cell lines can be discriminated by differing CD326 (EpCAM) compared to colon cancer EVs as demonstrated by binding to the respective capture beads (fig. 3).



#### Cancer cell EVs from ovarian cancer display different surface markers

We investigated surface proteins of EVs captured directly from ascites obtained from five ovarian cancer patients. Besides the tumor makers such as CD326 (EpCAM), CD133 (PROM1), CD44, common exosome markers CD9, CD63, and CD81, we detected markers indicating blood cell–derived vesicles, including CD4 and CD8 for T cells and CD14 for monocytes. Interestingly, samples

from different patients showed greatly different levels of key and CD49e, which indicate the presence of tumor-derived exosomes in the ascites.



### Analysis of surface markers on B cell EVs suggests presence of EV subpopulations

EVs from activated B cells were incubated with the 39-plex beads and stained with a cocktail of CD9, CD63, and CD81-APC antibodies or with selected single antibodies (fig. 5). With regard to B cell-specific markers, anti-CD19 beads showed stronger signals than anti-CD20 beads after staining with the antibody cocktail (APC median signal 11.3 and 5.4, respectively). We therefore conclude that less EVs were positive for CD20 than for CD19. Conversely, on all bead types CD20-APC signals were EVs and that B cell EVs most likely are CD9-negative. stronger than CD19-APC signals, suggesting that the amounts of CD20 per EV were higher compared to CD19. We propose a subpopulation of B cell EVs carrying high levels of CD20.

The anti-CD42a beads and anti-CD9 beads exhibited signals exclusively after staining with the CD9/63/81-APC antibody

cocktail. The signals on the anti-CD42a beads indicated the presence of platelets during cell culture. Therefore, we performed cell stainings after B cell isolation and indeed detected 90.5% CD42a-positive events when no gates and triggers were set (data not shown), confirming the presence of platelets within the isolated B cell fraction. We conclude that the signal on the anti-CD9 beads was most likely due to platelet For the analysis of *in vitro* activated B cell exosomes, we used specific staining antibodies to investigate potential exosome subpopulations. The signals for the activation markers CD80 and CD86 demonstrate that the activation status of the cells is reflected by the secreted vesicles.

# 35 20163 20181 2019 2010 20168 20186 20186 HIMDO 201428 REA Capture antibody bea **Figure 5**

Matrix profile of B cell EVs. Background-corrected APC median signal intensity of different capture antibody bead types after incubation with 32 µg EVs from activated B cells, followed by staining with CD19-APC, CD20-APC, CD80-APC, CD80-APC, CD86-APC Anti-HLA-DQ-APC, or a cocktail of CD9-APC, CD63-APC, and CD81-APC antibodies. REA and mlgG1 indicate isotype control beads.

## EVs bound to multiplex beads via different surface markers can be fixed

EVs derived from activated B cells

To enable the analysis of EVs from potentially infectious material, we established a protocol to fix the stained vesicles bound to



#### Figure 6

Surface marker profile of EVs captured from 120 µL of supernatant from a human embryonic kidney (HEK) cell culture. Shown is the APC median signal intensity of capture antibody bead types after incubation with the supernatant, followed by staining with CD63-APC with or without fixation. REA and mlgG1 indicate isotype control beads.

# Conclusion

- We developed a multiplex bead platform to simplify the analysis of the surface protein composition of extracellular vesicles.
- Vesicles can be captured directly from body fluids like ascites.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS is a registered trademark of Miltenyi Biotec and/or its affiliates in various countries worldwide. All other trademarks mentioned in this document are the property of their respective owners and are used for identification purposes only. Copyright © 2020 Miltenyi Biotec and/or its affiliates. All rights reserved.



multiplex beads for later flow cytometric analysis. Fixed and unfixed samples gave comparable results (fig. 6).

• EVs, which are bound to specific beads and stained using common exosome markers, can be detected using standard flow cytometry. Fixation is possible. Additional staining antibodies can reveal information on potential exosome subpopulations.